2-[18F]-fluoro-2-desoxy-D-glucose positron emission tomography initial staging impacts on survival in Hodgkin lymphoma

Table 2 Hazard ratio of clinical characteristics in the group of patients staged conventionally and with 2-[18F]-fluoro-2-desoxy-D-glucose positron emission tomography

	Five-year-EFS				Five-year-OS
	AS		MS		CS		MS
	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P
Age (> 45, ≤ 45)	1.89 (0.95-3.76)	0.067	1.75 (0.86-3.57)	0.121	2.97 (1.18-7.47)	0.020	6.59 (2.20-19.68)	0.001
Gender	1.32 (0.72-2.44)	0.362	0.85 (0.44-1.63)	0.628	2.00 (0.76-5.20)	0.155	0.83 (0.29-2.38)	0.739
B symptoms	2.19 (1.05-4.57)	0.036	1.76 (0.82-3.76)	0.140	2.27 (0.76-6.81)	0.142	1.44 (0.45-4.61)	0.532
Bulky	0.94 (0.50-1.79)	0.868	0.94 (0.48-1.84)	0.869	1.06 (0.40-2.77)	0.899	0.41 (0.13-1.22)	0.111
Early vs advance clinical stage	2.05 (1.09-3.85)	0.024	2.73 (1.19-6.24)	0.017	2.51 (0.96-6.55)	0.059	8.09 (1.05-61.85)	0.044
Stage IV disease	2.42 (1.32-4.42)	0.004	2.33 (1.20-4.50)	0.012	3.67 (1.52-8.88)	0.004	6.54 (1.82-23.48)	0.004
Serum albumin	1.09 (.057-2.07)	0.775	1.52 (0.71-3.25)	0.273	2.12 (0.71-6.37)	0.178	1.91 (0.53-6.87)	0.318
Hemoglobin	1.50 (0.79-2.85)	0.206	1.35 (0.67-2.71)	0.399	2.47 (1.02-5.96)	0.044	1.43 (0.48-4.29)	0.514
White blood cell count	2.11 (1.03-4.30)	0.039	1.62 (0.62-4.18)	0.319	2.55 (1.84-8.2)	0.041	1.68 (0.37-7.54)	0.495
Lymphocyte count	1.81 (0.95-3.44)	0.067	2.61 (1.27-5.3)	0.009	2.44 (0.99-6.00)	0.050	2.84 (0.95-8.51)	0.061
IPI (0-2, ≥ 3)	3.41 (1.80-6.47)	0.000	2.08 (1.07-4.08)	0.031	3.74 (1.43-9.77)	0.007	4.98 (1.38-17.86)	0.014

IPI: International prognosis index; OS: Overall survival; EFS: Event free survival; AS: Anatomical staging; MS: Metabolic staging; CS: Conventional stage.